China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply
CompanyDeals

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares
CompanyDeals

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
CompanyDrug

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansio
CompanyDeals

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
CompanyDrug

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer
CompanyDrug

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
Others

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros
CompanyDeals

Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers
CompanyDeals

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies
CompanyDeals

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Aosaikang's AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment
CompanyDeals

Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment

Kelun-Biotech's Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
CompanyDrug

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer